Feedback

Novavax applies to WHO for emergency use of Covid-19 vaccine

Source : 112 Ukraine

Novavax coronavirus vaccine is 96.4% effective against the original coronavirus variant and 86.3% effective against the British strain
11:42, 24 September 2021

vaccine
shutterstock.com

Novavax and the Serum Institute of India have applied to the World Health Organization for the use of the Novavax vaccine against coronavirus in emergencies. This is stated on the company's website.

"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world," said Novavax President and CEO Stanley C. Erck.

The Novavax coronavirus vaccine was reported to be 96.4% effective against the original coronavirus variant and 86.3% effective against the British strain. It was noted that Novavax planned to produce its vaccine at eight production sites, including the Indian Serum Institute.

As it was reported earlier, scientists of the Kyiv Polytechnic Institute and the Institute of the Epidemiology and Infectious Diseases have held the research of the spread of the fourth Covid-19 wave in Ukraine caused by the Delta strain.

Related: Over 9,000 new Covid-19 cases registered in Ukraine on September 23

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more